APR 06, 2016 1:30 PM PDT

Validation and Implementation of Whole-Exome Sequencing to Guide Precision Cancer Care

Speaker

Abstract


Cancer remains the second leading cause of death in the United States.  Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival.  Identification of genetic alterations by next generation sequencing (NGS), using either targeted sequencing or whole exome sequencing (WES) has become the standard of care in genomic medicine.  WES applies NGS technology to identify genetic variants in the coding regions (exons) of genes, harboring the majority of disease causing-mutations.  Using WES, it is currently feasible to not only detect a rapidly growing set of known clinically relevant mutations, but also identify novel or unexpected important variations, including constitutional mutations in cancer predisposing genes.  Thus far, the use of WES in cancer has largely taken place in the setting of large research studies.  Integration of WES into precision cancer care has lagged behind primarily due to technical challenges such as small and poor quality (FFPE) tissues and low-tumor purity samples that have not been rigorously validated in the clinical setting.  Another challenge is the analytical and computational approaches used to detect the wide-spectrum of mutations and genes queried by WES, which requires a comprehensive validation procedure to demonstrate the ability of the test to identify actionable mutations with high accuracy and at an acceptable analytical sensitivity.  The third challenge is a clinical challenge to attain meaningful interpretations of the genomic data which then can be used for patient care.  While these challenges are well recognized and despite a wide range of assays and platforms available, WES application in cancer has not yet been validated for the clinical laboratory and has not been fully characterized in the literature with regard to the analytic and clinical validity of the testing and the various types of relevant mutations.  The few existing guidelines given by professional societies give only high-level directions for implementing NGS testing geared primarily towards the use of targeted panels rather than WES.  By all accounts, New York State-Department of Health (NYS-DOH) requirements are among the most rigorous guidelines yet published and are likely to serve as a paradigm for suggested future type of guidelines that might be required by the Food and Drug Administration (FDA).  These efforts are also in line with the new precision medicine initiative announced by U.S. President Obama with the intent to bring us closer to curing cancer and give all of us access to a more personalized and genomic-driven medicine.
   This presentation describes the development and analytical characteristics of NYS-DOH approved clinical exome cancer test suitable for simultaneous detection of somatic dingle nucleotide variants (SNVs), indels and copy number alterations (CNAs) using the Agilent HaloPlex capture platform and the Illumina HiSeq2500 system for sequencing.  Initial validation has focused on actionable mutations in five principal, clinically relevant genes and according to NYS-DOH guidelines.  The automated computational framework for data analysis, variant interpretation and reporting is also discussed. 

The objectives of this presentation are:

  • To describe the development and analytical characteristics of a New York State-Department of Health (NYS-DOH) approved clinical Exome Cancer Test suitable for simultaneous detection of somatic single nucleotide variations (SNVs), indels and copy number alterations (CNAs). 
  • To discuss the automated computational framework for data analysis, variant interpretation and reporting of whole exome sequencing (WES) data, using examples of clinical cases and reporting of WES results. 

Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
DEC 09, 2021 11:00 AM PST
C.E. CREDITS
DEC 09, 2021 11:00 AM PST
Date: December 09, 2021 Time: 11:00am (PDT), 2:00pm (EDT) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new...
APR 06, 2016 1:30 PM PDT

Validation and Implementation of Whole-Exome Sequencing to Guide Precision Cancer Care



Show Resources
Loading Comments...
Show Resources